DK2217581T3 - Substituerede cyclopentaner med prostaglandinaktivitet - Google Patents

Substituerede cyclopentaner med prostaglandinaktivitet

Info

Publication number
DK2217581T3
DK2217581T3 DK08848280T DK08848280T DK2217581T3 DK 2217581 T3 DK2217581 T3 DK 2217581T3 DK 08848280 T DK08848280 T DK 08848280T DK 08848280 T DK08848280 T DK 08848280T DK 2217581 T3 DK2217581 T3 DK 2217581T3
Authority
DK
Denmark
Prior art keywords
substituted cyclopentanes
prostaglandin activity
prostaglandin
activity
cyclopentanes
Prior art date
Application number
DK08848280T
Other languages
Danish (da)
English (en)
Inventor
Jeremiah H Nguyen
Robert M Burk
Yariv Donde
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2217581(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2217581T3 publication Critical patent/DK2217581T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)
DK08848280T 2007-11-09 2008-11-05 Substituerede cyclopentaner med prostaglandinaktivitet DK2217581T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98684907P 2007-11-09 2007-11-09
US12/265,062 US9006464B2 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity
PCT/US2008/082469 WO2009061811A1 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglanding activity

Publications (1)

Publication Number Publication Date
DK2217581T3 true DK2217581T3 (da) 2013-10-21

Family

ID=40524829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08848280T DK2217581T3 (da) 2007-11-09 2008-11-05 Substituerede cyclopentaner med prostaglandinaktivitet

Country Status (21)

Country Link
US (1) US9006464B2 (enExample)
EP (1) EP2217581B1 (enExample)
JP (1) JP2011503089A (enExample)
KR (1) KR20100101097A (enExample)
CN (2) CN101952261B (enExample)
AR (1) AR069228A1 (enExample)
AU (1) AU2008324793B2 (enExample)
BR (1) BRPI0818902A2 (enExample)
CA (1) CA2705150C (enExample)
CL (1) CL2008003332A1 (enExample)
CO (1) CO6280480A2 (enExample)
DK (1) DK2217581T3 (enExample)
ES (1) ES2432058T3 (enExample)
IL (1) IL205604A (enExample)
MX (1) MX2010005105A (enExample)
NZ (1) NZ585517A (enExample)
RU (1) RU2481339C2 (enExample)
TW (1) TWI411438B (enExample)
UA (1) UA99840C2 (enExample)
WO (1) WO2009061811A1 (enExample)
ZA (1) ZA201003304B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3991734B1 (en) 2019-06-28 2024-11-27 Gurus BioPharm Inc. Agent for the treatment of alopecia and promoting hair growth

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012A (en) * 1850-01-15 Improvement in mowing-machines
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
JPS5623984B2 (enExample) * 1973-04-19 1981-06-03
US4065472A (en) * 1975-09-29 1977-12-27 Pfizer Inc. 5-(2-Carboxythiophen-5-yl)-16-aryloxy-α-tetranor-ω-tetranorprostaglandins
GB1563201A (en) * 1975-11-05 1980-03-19 Shell Int Research Preparation of herbicidally acitve alanine derivatives
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
WO2008094958A1 (en) 2007-02-01 2008-08-07 Allergan, Inc. Thiophene derivatives useful as medicaments for treating ocular hypertension

Also Published As

Publication number Publication date
ZA201003304B (en) 2014-03-26
EP2217581B1 (en) 2013-07-31
RU2481339C2 (ru) 2013-05-10
CN101952261B (zh) 2013-06-12
TWI411438B (zh) 2013-10-11
WO2009061811A1 (en) 2009-05-14
CL2008003332A1 (es) 2011-08-12
AR069228A1 (es) 2010-01-06
CA2705150A1 (en) 2009-05-14
EP2217581A1 (en) 2010-08-18
CA2705150C (en) 2016-06-14
IL205604A (en) 2014-06-30
IL205604A0 (en) 2010-11-30
US9006464B2 (en) 2015-04-14
US20090124676A1 (en) 2009-05-14
CO6280480A2 (es) 2011-05-20
UA99840C2 (ru) 2012-10-10
KR20100101097A (ko) 2010-09-16
WO2009061811A8 (en) 2009-07-02
JP2011503089A (ja) 2011-01-27
AU2008324793B2 (en) 2013-12-05
TW200934500A (en) 2009-08-16
NZ585517A (en) 2012-08-31
CN102977048A (zh) 2013-03-20
BRPI0818902A2 (pt) 2015-05-12
ES2432058T3 (es) 2013-11-29
CN101952261A (zh) 2011-01-19
MX2010005105A (es) 2010-05-27
RU2010122681A (ru) 2011-12-20
AU2008324793A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
EP2288997A4 (en) DISTRIBUTED CACHE ARRANGEMENT
BRPI0914743A2 (pt) estrutura
DK2250161T3 (da) Forbindelser med CRTH2-antagonistaktivitet
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0810702A2 (pt) Catalisador
BRPI0806537A2 (pt) Indazóis substituídos por 5-piridinona
BRPI0918344A2 (pt) composição catalítica
DK2211626T3 (da) Bagværk
DE602008003400D1 (de) Wabenstruktur
EP2202211A4 (en) HONEYCOMB STRUCTURE
BRPI0806506A2 (pt) Indazóis substituídos por 5-furopiridinona
FI20086154A0 (fi) Katalyyttirakenne
EP2514426A4 (en) CONNECTION WITH ANTI-INFLAMMATORY EFFECT
DK2217581T3 (da) Substituerede cyclopentaner med prostaglandinaktivitet
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
PL2143693T3 (pl) Struktura plastra miodu
DE602009001201D1 (de) Wabenstruktur
BRPI0910931A2 (pt) ciclopentanos substituídos terapêuticos
BRPI0819707A2 (pt) Ciclopentanos substituídas tendo atividade de prostaglandina
IT1390861B1 (it) Composti ad attività antimalarica
FI20096202A0 (fi) Biologinen regeneraatti
BRPI0910856A2 (pt) pista sólida
BRPI0907913A2 (pt) Ciclopentanos substituídos tendo atividade de prostaglandina
BRPI0814627A2 (pt) Derivados de malonamida com atividade antitrombótica
DE602009000269D1 (de) Wabenstruktur